GORAB

Across TCGA pan-cancer cohorts, GORAB Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GORAB data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GORAB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GORAB expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUAD, SKCM, and LUSC are the cancer types where GORAB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.057	0.709	<.001	28	view →
SKCM	DFS	Median	II,III,IV	0.562	0.208	.014	10	view →
LUSC	OS	Median	All	0.173	0.724	.012	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GORAB–LUAD (OS)

Open the LUAD breakdown →